When considering EZH2 as a therapeutic agent, one must take into account these parameters, together with an understanding of the functional consequences of EZH2 mutations and the cancer patient’s specific cellular oncometabolome with respect to systemic inflammatory reactions. This evidence concerns the gene EZH2 and cancer.